about
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophilsTarget interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growthTKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CMLIdentification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816VPhenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemiaA new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM)Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.Comparative oncology: The paradigmatic example of canine and human mast cell neoplasmsLudwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectivesA kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CMLEffects of ibrutinib on proliferation and histamine release in canine neoplastic mast cellsThe Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and PerspectivesSTAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms
P50
Q28480417-684B9C9F-AF28-4825-B9DE-2C70BAE1FDF7Q28828739-B63D504B-4F57-4DA7-A7FD-31048994BF92Q30357188-FD1C82AF-5A7A-469C-AC67-A390DC38EBCCQ36406996-BCB0336D-085C-47EB-92E0-08FBFB6582A0Q36977305-65B656E6-A72E-4FE6-86D9-EF13E675EB30Q37144902-97832FCE-A77E-48D0-8B9B-C06004873AA7Q37529231-94C82B7A-3DC8-40C6-8F8E-35A95AD5BD0BQ38062360-BCE16381-CB64-4275-9CBD-0AE1259C991DQ38193659-20047C2D-5F5D-4634-A35D-864762EFA8BDQ38761287-FA15B184-C1F8-4036-8501-24FA682F1A63Q38866094-334BA44B-5E1A-4D90-A4DF-49B726ACCAF3Q39010282-06B2C71C-BC0A-4614-B7D7-657834A4B07AQ39010730-061FE30F-DFEB-459A-87C4-0707F12DBC26Q39089887-A4C3C559-7CC0-4DD4-A9CC-257B2C327930Q39093823-52EB2197-7138-4EB2-8EFB-BB2B5865A295Q39348704-24BA19F6-FE41-41D5-A34C-738BD2134E74Q39375748-709AF328-98E6-46E3-AFB9-7898AB14BD46Q39523051-FFA439C2-8652-4D2C-93ED-6110D4A8465DQ39606792-F7BA6D80-8BF3-4455-B821-C4B229E6247AQ39671424-C76A60B0-615F-45BD-84CD-553A346B6351Q39689493-91F19373-91C7-421B-9A4D-2DCE3AD45E49Q39741527-8EB626F6-47C7-40AB-A7B3-F76E88B3A8C4Q39947810-75A5C6BB-748D-40A8-80D4-543A95242D09Q40097396-2029530F-DEA0-4D1B-9B33-7B7A14BDEF47Q40582535-FD457364-70FF-4438-8519-49BEBDF4A2DAQ41668621-D5DD3DA2-D12A-4AD8-B453-65C65CC2CE9AQ45977986-A8BF690B-C361-42CC-8E00-4BB80F4B63EAQ47653225-E97DA5EB-BD14-4C07-B03D-A7CD99C52E6BQ48010780-1C16E37D-15DB-4140-A2F2-B16C13CDDF9AQ48104415-71CF2749-A3F7-4887-9F9F-69871E637FCAQ48120081-9D292CC8-DD13-47F0-85B2-CEAC2C1AF499Q48291629-7B540DF4-40D3-4D38-874F-DD785DD490B7Q50035104-3C4E9E39-B1FD-477E-BEEE-2A9FCD31EC94Q57174064-CDAC6683-E811-4021-8058-EAD0D8F8CB3FQ57176232-89260CD4-AA10-4E72-9C04-981FA6304A16Q91318439-921D8261-5BCE-40CB-B46A-AF895B496818Q91732120-35068F41-97DC-4502-85EE-A99DEC3ECE4BQ92984930-D572EF7B-6C23-4478-B2BE-2207A3511186Q93188811-6F53E687-6821-4CEB-BAE8-39F4EF2CF788
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Emir Hadzijusufovic
@ast
Emir Hadzijusufovic
@en
Emir Hadzijusufovic
@es
Emir Hadzijusufovic
@nl
Emir Hadzijusufovic
@sl
type
label
Emir Hadzijusufovic
@ast
Emir Hadzijusufovic
@en
Emir Hadzijusufovic
@es
Emir Hadzijusufovic
@nl
Emir Hadzijusufovic
@sl
prefLabel
Emir Hadzijusufovic
@ast
Emir Hadzijusufovic
@en
Emir Hadzijusufovic
@es
Emir Hadzijusufovic
@nl
Emir Hadzijusufovic
@sl
P106
P21
P31
P496
0000-0001-7409-4204